{"id":755879,"date":"2023-05-08T08:12:50","date_gmt":"2023-05-08T12:12:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/"},"modified":"2023-05-08T08:12:50","modified_gmt":"2023-05-08T12:12:50","slug":"cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/","title":{"rendered":"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, May  08, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zMLmVk0XtdQKWpMV2U_KfAQDJQKyXmjGw77x4R_ATZfS8xQxBQ4sHGSGTHmYFxzLmwMZjzPU33aKa5_o1k5lO_ZTV1DHRs77-1FiYPtlT_Hv6DN9nUQ4pPYav_YRO9O8EChG5As_MdL-_TekD5o6Bq7RoVQYgpG-k_b0VSGZMR6wfyI9gBmyMXsKwqBkLv8QHQtSZaOcSA7_QO0KxIn4ZoplSkMxgMqzhSgJ2THC4sxef8zFE_1mOOm8RrDnE48g\" rel=\"nofollow noopener\" target=\"_blank\">Cue Biopharma, Inc.<\/a>\u00a0(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient\u2019s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023.<\/p>\n<p align=\"left\">During the fireside chat, Cue Biopharma will provide an update on ongoing clinical trials with CUE-101 and CUE-102, their lead IL-2 based oncology drug product candidates,\u00a0as well as the company\u2019s corporate and business development initiatives.<\/p>\n<p align=\"left\">\n        <strong>Presentation Details:<br \/><\/strong><br \/>\n        <strong>JMP Securities Life Sciences Conference<br \/><\/strong><br \/>\n        <strong>Date and Time:<\/strong> Monday, May 15 at 3:30 p.m.\u20134:00 p.m. EDT<br \/><strong>Webcast Link:<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B05Hm6h8l-7AlQvTgyZPj8sgs8LzucIeQUYqX6fdZuieMoJ_5xYraANzVyS94SnPFamGuW87l7iV5ehbWRKHRpw6Kx3boGT9sT4dIGaQNJ3J75B1AR94RoWPZ-LbLdWzDLdD5wOMGk4whfEG1c5Kig==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/wsw.com\/webcast\/jmp59\/cue\/1536481<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mWkcX-NlgDVFXSQzjNVV84d8kea00bGdvoPTUDC09QV2W901gqMikskIrgndTX_BLmUYnCGuuOASDcra_aALOcGWZ1KKspu8DIbVsBAdDI0=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/><\/a><strong>Presenter:\u00a0<\/strong>Daniel Passeri,\u00a0chief executive officer,\u00a0Cue Biopharma<\/p>\n<p align=\"left\">A live and archived webcast of the presentation will be available on the Events page in the Investors and Media section of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9tpdOy9bAUZgJGs3PEQp9t1Tatyu1tiGkL0QupbrDEyCJsVZmNXhSkfpwEWi8sM3We7rJn4aPABYrcAWbNisalDEtH8OwbPZBQgV65mN1isUvpOiizHQwrNjrYBeHOnepX1sdkgFkTDkf_kXfaGkYQw1geRvoXVad5Y4ZpATeLgPV7R04_h4CyEyosotSGgSURalo6Fdtxu-rgD8Ob6rmMR7-bUK0CkyfZIGIqMY2zmirDqmAu99mK9_4GxmtLrvNPOttyc26bcUd7_s1Q1TQw==\" rel=\"nofollow noopener\" target=\"_blank\">www.cuebiopharma.com<\/a>. The webcast will be archived for 30 days.<\/p>\n<p align=\"left\">\n        <strong>About\u00a0Cue Biopharma<\/strong><br \/>\n        <br \/>Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient\u2019s body. The company\u2019s proprietary platform, Immuno-STAT\u2122\u00a0<em>(Selective Targeting and Alteration of T cells)<\/em>\u00a0and biologics are designed to harness the body\u2019s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic modulation.<\/p>\n<p align=\"left\">Headquartered in\u00a0Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.<\/p>\n<p align=\"left\">For more information please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9tpdOy9bAUZgJGs3PEQp9ii61X4erkJ3tUIBaGOOlJgifBQU_uU0gW9BQQzkUUZgCANzQTY2QOEglPMeFIN1ZAxLRo8_ccYwiwwlH2ZPtB6NoYjYPk5Elfct0gkNLZqYpIYKi8QOyftoJhZMFXC68iH5a7n2EE1ypyRKEJBmxygrudtr3HBGSkd-8zaJqYCFb4BnEKRE2eqLZPdjhyQz-jJQYAhPbqFHJ2O54oqlCStUTcd6z0xUxbFtgoYpHpRq_3EsUP57i0uCfza6LpwnPmlG-m16DHljyK4uEMBxS5OBx-L1Hx5pqz7fVfraZUImcbIH-CYBRjm8jNkMSFU8xDz6hDbYDAwkbXvbI-8MfTMiE27t6ukjunAdzDzEi-hccVgr1PvGIZa9M9LHOaxi-D5kYxclKXDW6khiGCQs0qYKtfnEztsoP2sKxMJpmV-ihIbtevPDpbEY5XNSw5I7IYVuFroeKs52AAz4cNfgYlY=\" rel=\"nofollow noopener\" target=\"_blank\">www.cuebiopharma.com<\/a>\u00a0and follow us on Twitter at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B05Hm6h8l-7AlQvTgyZPj9AW_iHZLSDIUhsiAuRT-c4Ydjwg0kbj-9Y7pf0wxY3ptvLAq0ilDPSZ4g56Or3BhySLUu1XZ2KgESXiN-Nn6R6ququ0ujwTL6SGITaJrjGKbLqrIvdsX99ajSgBAiZe4moTDyM_wMHYrCEf3FbgKl8_daSibxkj5N8lU6hC4AHJsRznBVGPd43MUeZotKYdDswUouEeKoxRHeHFc9lkmdK_wYjHiTrnETuzCGcmBFdWbFkh35HvoO4WdE9FaFdOzuv0OhimeZeYzK6svd06svsm1yu0VK5qH8Ik2H_Hgz3l\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/twitter.com\/CueBiopharma<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements\u00a0<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding the company\u2019s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company\u2019s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cseek,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201clikely\u201d or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company\u2019s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company\u2019s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company\u2019s limited operating history, limited cash and a history of losses; the company\u2019s ability to achieve profitability; potential setbacks in the company\u2019s research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (\u201cFDA\u201d) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the company\u2019s trials; negative or inconclusive results from the company\u2019s clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company\u2019s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company\u2019s ability to obtain adequate financing to fund its business operations in the future; operations and clinical the company\u2019s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations sections of the company\u2019s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Marie Campinell<br \/>Senior Director, Corporate Communications<br \/>Cue Biopharma, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h0ZtjHXK_MHGobTSsPqEgn0wGd-kJrbjszvJzRqp2VNEhpCkyiKdRG1m6hS4Ds1M2hYmUuDB74mVytHWbiTJf9laIRXcgk5DNcU8ymtI-nw=\" rel=\"nofollow noopener\" target=\"_blank\">mcampinell@cuebio.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Maya Romanchuk<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QxmOd7i9AWnJZU63lPu3JgJ5adMYgoVrK-ltDnhes9QaffwMArSW1rwjH_uIzzHVr73ER7sWDIy8xkcfE5AMF7Asq4CtEkWy-KtsXDZEudG_hTWJOBj_8Rx-_LATTq7H\" rel=\"nofollow noopener\" target=\"_blank\">mromanchuk@lifescicomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2FmZDNjYjMtMjIxZi00YmU1LTgyNzktYTExZDBlODg1NTRmLTExMDQyNjM=\/tiny\/Cue-Biopharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, May 08, 2023 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc.\u00a0(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient\u2019s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023. During the fireside chat, Cue Biopharma will provide an update on ongoing clinical trials with CUE-101 and CUE-102, their lead IL-2 based oncology drug product candidates,\u00a0as well as the company\u2019s corporate and business development initiatives. Presentation Details: JMP Securities Life Sciences Conference Date and Time: Monday, May 15 at 3:30 p.m.\u20134:00 p.m. EDTWebcast Link:https:\/\/wsw.com\/webcast\/jmp59\/cue\/1536481Presenter:\u00a0Daniel Passeri,\u00a0chief executive &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-755879","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, May 08, 2023 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc.\u00a0(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient\u2019s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023. During the fireside chat, Cue Biopharma will provide an update on ongoing clinical trials with CUE-101 and CUE-102, their lead IL-2 based oncology drug product candidates,\u00a0as well as the company\u2019s corporate and business development initiatives. Presentation Details: JMP Securities Life Sciences Conference Date and Time: Monday, May 15 at 3:30 p.m.\u20134:00 p.m. EDTWebcast Link:https:\/\/wsw.com\/webcast\/jmp59\/cue\/1536481Presenter:\u00a0Daniel Passeri,\u00a0chief executive &hellip; Continue reading &quot;Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-08T12:12:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference\",\"datePublished\":\"2023-05-08T12:12:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/\"},\"wordCount\":810,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/\",\"name\":\"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=\",\"datePublished\":\"2023-05-08T12:12:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/","og_locale":"en_US","og_type":"article","og_title":"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference - Market Newsdesk","og_description":"BOSTON, May 08, 2023 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc.\u00a0(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient\u2019s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023. During the fireside chat, Cue Biopharma will provide an update on ongoing clinical trials with CUE-101 and CUE-102, their lead IL-2 based oncology drug product candidates,\u00a0as well as the company\u2019s corporate and business development initiatives. Presentation Details: JMP Securities Life Sciences Conference Date and Time: Monday, May 15 at 3:30 p.m.\u20134:00 p.m. EDTWebcast Link:https:\/\/wsw.com\/webcast\/jmp59\/cue\/1536481Presenter:\u00a0Daniel Passeri,\u00a0chief executive &hellip; Continue reading \"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-08T12:12:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference","datePublished":"2023-05-08T12:12:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/"},"wordCount":810,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/","name":"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=","datePublished":"2023-05-08T12:12:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzE5NyM1NTc4NDMyIzIwOTI2OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-at-the-upcoming-jmp-securities-life-sciences-conference-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=755879"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755879\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=755879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=755879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=755879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}